GALECTIN THERAPEUTICS INC — Director's Dealing 2020

Feb 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2020-02-13

Reporting Person: Uihlein Richard E (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-13	Common Stock	M	46875	$2.39	Acquired	7864553	Direct
2020-02-13	Common Stock	M	18638	$4.72	Acquired	7883191	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-13	Stock option (right to buy)	$2.39	M	46875	Disposed	2027-12-14	Common Stock (46875)	Direct
2020-02-13	Stock option (right to buy)	$4.72	M	18638	Disposed	2029-01-16	Common Stock (18638)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	27710	Indirect

Footnotes

F1: The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.

F2: The options were issued pursuant to Galectin Therapeutics' Amended and Restated 2009 Incentive Stock Plan.

F3: The options became fully vested on December 14, 2018.

F4: The options became fully vested on January 16, 2020.